- Find Out More About:
- R&D Grants Australia
The prevalence of diabetes mellitus is proliferating in the Netherlands. Country’s diabetes care is essentially focused on primary health care, with the responsibility of general practitioners for many areas of care. the increase in the prevalence of obesity is another point of concern, leading to a massive increase in the number of patients with metabolic syndrome. According to Renub Research analysis report, Netherlands Diabetes Market is forecasted to reach USD 4.48 Billion by 2025.
During the last decade, The Netherlands has seen a rise in the incidence of type 2 diabetes. Almost half Netherlands population suffered from a minimum of one chronic illness in the last decade. DM is one of the diseases with a high burden of disease and a decrease in the quality of life in the country. But the great news is that with the ageing of the Dutch population and also the prevalence of obesity as a major risk factor for diabetes, the survival rate is improving. The same number of screening programs are being presented in the Netherlands.
The Netherlands has implemented the National Action program Diabetes in the last decade to fight against diabetes. it had been aimed to use a particular implementation plan to introduce the Care Standard (CS) for diabetes and to pilot it in several regions. Roche received the CE Mark for its Accu-Chek Sugar View app in December 2019. Accu-Chek Sugar View is that the first app that checks blood glucose ranges without the necessity for a blood glucose meter by taking pictures with a smartphone camera.
The impact of COVID-19 on Netherlands Diabetes Market
The spending on healthcare has increased in the nation because of this the marketplace for diabetes management will increase consistent with Renub Research analysis. In this report, we are covers the impact of coronavirus on the diabetic market of Netherlands.
The market of CGM & SMBG Device, Insulin Pen and Insulin Pump is growing thanks to the rising awareness for diabetes in Netherland. Diabetes care within the Netherlands has reached a high level of quality, but there’s still a chance for further improvement. Not only is it a medical challenge but a minimum of as much a burden for the Dutch economy and society. To fight with these risk factors, Netherlands unrolled national health programs. In 2018, The National Prevention Agreement which was approved and it sets out ambitious goals to create the Netherlands healthier by 2040, but it had been in March 2019 that they’re still far from reach.
Wide disparities exist in the prevalence of chronic diseases:
Based on self-reported data from the EU Health Interview Survey, one in six people in the Netherlands accept hypertension, one in eighteen with asthma, and one in twelve with chronic depression. Wide disparities exist in prevalence by education level. People with rock bottom level of education are nearly 3 times as likely to measure with diabetes and 35% more likely to measure with asthma as those with the higher level of education.
Low numbers of avoidable hospitalisations suggest effective primary care:
The Netherlands features a low number of avoidable hospitalisations, indicating that medical care and outpatient secondary care help to stop serious symptoms from developing, also as relatively low avoidable mortality. The numbers of avoidable hospital admissions for asthma, congestive coronary failure, COPD and acute complications of diabetes are less than in most other EU countries. Efforts to enhance (coordination in) maternal care have resulted during a reduction of perinatal and neonatal mortality rate rates since 2000. Furthermore, the 30-day case fatality ratios following hospital admissions for acute myocardial infarction and stroke are generally better than those of states with data available.
Request a free Brochure copy of the report:
Market Summary:
By CGM: The market and market share of CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement are covered in this research report.
By Self Monitoring Blood Glucose Device: SMBG Market by Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement are given in the report.
By Insulin Pen: The number of Insulin Pen Users, Types Disposable, Reusable and Smart Insulin Pen, Insulin Pen Needle Market, Reimbursement Policies are covered in this research report.
By Insulin Pump: This research report covers Insulin Pump Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies.
By Company: This research report has covered Company overview, recent developments/ initiatives and revenue analysis for B. Braun Melsungen AG, Eli Lilly and Company, Artsana S.p.A, BD, Novo Nordisk A/S, Owen Mumford Ltd, Ypsomed AG, Medtronic, Insulet Corporation, LifeScan Inc., Abbott Laboratories, DexcomInc and Roche.
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:Renub ResearchPhone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)Email: info@renub.comWeb: Follow on Linkedin:
